Upfront alemtuzumab-based MUD HSCT in childhood aplastic anemia: excellent survival and GRFS, but immune challenges persist [0.03%]
Audrey Françoise Petit,Arthur Sterin,Virginie Gandemer et al.
Audrey Françoise Petit et al.
Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma [0.03%]
Laura B Oswald,Xiaoyin Li,Lisa M Gudenkauf et al.
Laura B Oswald et al.
This was the first study to assess patient-reported outcome (PRO) trajectories among patients with relapsed/refractory multiple myeloma (RRMM) receiving standard of care chimeric antigen receptor T-cell therapy (CAR-T) and to compare PRO tr...
Allogeneic hematopoietic stem cell transplantation in elderly patients with AML and MDS: navigating risks and optimizing outcomes [0.03%]
Mingyang Wang,Jieya Luo,Didier Blaise et al.
Mingyang Wang et al.
The growing burden of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) among aging populations underscores the critical need for tailored treatment strategies for elderly patients. While allogeneic hematopoietic stem cell tr...
Symptom-guided approach to central nervous system complications in allogeneic hematopoietic cell transplant recipients: Best practice recommendations from the EBMT Practice Harmonisation and Guidelines committee [0.03%]
Roser Velasco,Martin Schmidt-Hieber,Olaf Penack et al.
Roser Velasco et al.
Central nervous system complications (CNSC) after allogeneic hematopoietic cell transplantation (allo-HCT) are relatively common and may have a major impact on patients´ outcomes. Neurological symptoms may occur at any point during the pos...
Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group [0.03%]
Rafael Colmenares,Eva Barragán,Rebeca Rodríguez-Veiga et al.
Rafael Colmenares et al.
Acute myeloid leukemia (AML) is a heterogeneous malignancy with a poor prognosis. Genetic and molecular profiling help guide treatment decisions, including the use of allogeneic hematopoietic stem cell transplantation (allo-HSCT), to reduce...
Correction: Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial [0.03%]
匹夸琳布用于适合移植的原发性骨髓纤维化患者：HOVON-134 二期临床试验最终分析订正案
R Van Dijck,B van der Holt,A E C Broers et al.
R Van Dijck et al.
Published Erratum
Bone marrow transplantation. 2026 May 5. DOI:10.1038/s41409-026-02900-6 2026
Parous female donor confers superior relapse protection in Haplo-PBSCT: A multicenter study of ATG/PTCy combination-based GVHD prophylaxis in AML/MDS [0.03%]
移植后GVHD预防采用ATG/PTCY联合方案的单倍型相合外周血干细胞移植中带卵泡的女性供者移植物可提供更佳的复发保护：多中心研究
Xingying Li,Wenjuan Zhang,Jian Zhou et al.
Xingying Li et al.
Impact of donor and recipient EBV serostatus on transplant outcomes in patients with acute leukemia after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide: Infectious Diseases Working Party EBMT retrospective study [0.03%]
单倍型相合造血干细胞移植后序贯环磷酰胺治疗急性白血病受者EBV供受者状态对移植结局影响的回顾性研究——EBMT感染工作组研究
Jan Styczynski,Gloria Tridello,Inge Verheggen et al.
Jan Styczynski et al.
Excellent outcomes using a novel reduced intensity conditioning with thiotepa and post-transplant cyclophosphamide for HLA-matched related donor transplant in adolescents and adults with sickle cell disease [0.03%]
用于镰状细胞疾病匹配供者的新型低强度预处理方案（硫替pa和移植后环磷酰胺的造血干细胞移植的出色结果成年人中的临床研究
Reem Alasbali,Mohsen Alzahrani,Karina Wilkerson et al.
Reem Alasbali et al.
Myeloablative HLA-matched related donor (MRD) hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for children with sickle cell disease (SCD), achieving survival rates over 90%. However, optimal conditioning f...
Goals-of-care transition after an allogeneic hematopoietic stem-cell transplantation: A cross-sectional survey among hematologists on associated challenges [0.03%]
异基因造血干细胞移植后的照护目标转换：一项关于血液病学家面临挑战的横断面调查
Anne Pralong,Steffen T Simon,Marco Herling et al.
Anne Pralong et al.